# Respiratory Syncytial Virus (RSV) vaccine

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/respiratory-syncytial-virus-rsv-vaccine
Canonical HTML page: https://getbiobrief.com/entity/respiratory-syncytial-virus-rsv-vaccine

## Timeline

- **2026-07-20**: Cramer Endorsement & 109% YTD Gain — Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
- **2026-06**: Quarterly Update — Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
- **2022**: Post-Pandemic Decline — Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
- **2020**: COVID Vaccine Success — Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

## Recent coverage (1 stories)

### After 109% Rally, Moderna’s Pipeline Progress and 10% Revenue Goal
2026-07-21 00:07:40 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks.
Full story: https://getbiobrief.com/story/moderna-bio-pipeline-revival-109

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.